Respond to prefers-color-scheme dark in app web views

Follow section front redirects in Spectrum

Enable NLP source in PCS for load testing

Switch off the News Alerts Survey Widget when we have enough responses

Poll to determine if new LUF updates are available

Allows the winning A/B test variant to be turned on without Spectrum deployment

Show infinite scrolling sections in Assembler MultiView

Show option for NLP article summaries in Action Bar

A general feature flag for Recipe Features that aren't yet released

Feature flag for media team features that aren't yet released

Use new Orca video player for preroll plugin in Spectrum

Show the snow tracker (instead of the heat tracker) on Spectrum

Ask Amy: My boyfriend just confessed he’s almost $20,000 in debt

Miss Manners: Is it inappropriate to reach out to old girlfriends?

Carolyn Hax: Longtime friend won’t forgive being last-minute canceled for a guy

Biden confronts campus protests; Trump hedges on accepting election results

Kristi Noem just won’t stop talking about killing her dog

Noem’s dog-killing isn’t popular, though Trump supporters are divided

Strangers help Sesame Street puppeteer after heirloom necklace was stolen

Teen grabs wheel when driver passes out and school bus veers into traffic

Cat climbed into Amazon return box, found alive 630 miles away

The new cure-all for vacation excess: the IV drip 

What’s the best bus to New York? We tested 5 for comfort and value.

Adaptive equipment is making national parks more inclusive

The Post endorses April McClain Delaney and Tom Royals for Maryland’s 6th District

On Press Freedom Day, little to celebrate for Hong Kong’s journalists

Young Georgians want to be part of Europe. Their government is in the way.

In photos: At least 39 dead as historic flooding hits southern Brazil

Sea level rise brings new era of dangerous flooding

Michael Cohen keeps broadcasting despite being a witness

In a pinch, the Nationals finally find some offense

Is Pastis as good as our food critic thought? He sent spies to find out.

The Capitals, a team in transition, know what they want this offseason

Trump Media auditor charged by SEC with ‘massive fraud’

Google’s empire is massive. A judge will soon rule if it’s a monopoly.

Five tech products we actually like

The New York Times, alone in its outrage over access to Biden

The ‘Access Hollywood’ video cemented Trump’s air of invincibility

Stephen A. Smith would like even more of your attention

Confident of victory over Ukraine, Russia exhibits Western war trophies

Two women are seeking Mexico’s presidency. But the race is about a man.

Hamas in Cairo for hostage talks as Israel briefs aid agencies on Rafah

Toya Jordan Sarno/Bloomberg News

The Food and Drug Administration is planning new steps to encourage the development of nonaddictive alternatives to opioid pain medications, Commissioner Scott Gottlieb said in an interview.

As part of the effort, the agency plans to withdraw its existing 2014 guidance to the drug industry on pain medicines. That document is overly broad, Gottlieb said, and is sometimes a barrier to new products and innovations. The current guidelines call for a large number of studies to get FDA approval for general use for chronic pain, he added.

Over the next six to 12 months, the agency plans to issue several documents intended to spur development of medications for specific types of pain. The result should lead to smaller clinical trials, faster approvals and quicker launches of novel therapies, Gottlieb said.

One of the advisories will provide drug companies information on what the FDA is looking for in non-opioid medications for chronic pain, while another will detail how manufacturers can show that their product reduces patients' exposure to opioids for acute pain. Yet another will update drugmakers on how they should assess the risks of illicit use of their drugs, a factor in FDA reviews of drugs.

The move is the latest of varied FDA efforts to combat the opioid epidemic, which Gottlieb <a href="https://www.washingtonpost.com/news/to-your-health/wp/2017/05/23/fda-commissioner-gottlieb-calls-for-more-forceful-steps-to-curb-opioid-epidemic/?utm_term=.219081bb6a2f">has repeatedly said is a top agency priority</a>. On Tuesday, for example, the agency sent warning letters to four online networks operating 21 websites that illegally market unapproved medications. It directed the networks to immediately stop selling the products.

Other FDA officials say they hope that new road maps for bringing non-opioid pain medications to market will encourage drug companies to focus more intently on the field. And overall, they say, the drug industry is moving toward more-targeted therapies and away from the broad use of medications.

Keith Humphreys, a Stanford University psychiatrist, praised Gottlieb's efforts on the opioid epidemic overall but expressed skepticism that the new guidances would make a big difference. He said that the biggest problem is not a lack of non-opioid alternatives but that <a href="https://www.washingtonpost.com/national/health-science/a-quarter-of-adults-with-sprained-ankles-were-prescribed-opioids-in-the-er/2018/07/27/112cf916-9119-11e8-8322-b5482bf5e0f5_story.html?utm_term=.08d373d87e5d">physicians are still prescribing opioids too often</a>.

“Doctors have been trained since the 1990s that when they hear about pain, they pull out their pads and write prescriptions for opioids,” he said. “If you are a pharmaceutical company, that’s what worries you. It’s marginally helpful if the FDA says we will give you a faster review. But your main concern is that if doctors see pain, they say, that means Vicodin.”

Gary Mendell, founder and chief executive of Shatterproof, a nonprofit organization working to combat addiction, applauded Gottlieb's announcement and said it will raise the bar for FDA approval of opioids as well as promote the development of non-addictive alternatives.

As more non-opioid pain medicines enter the market, he added, pressures will mount for  more doctors to prescribe them and more insurers to pay for them.

The Centers for Disease Control and Prevention has reported that prescriptions for opioids have <a href="http://annals.org/aim/article-abstract/2698111/opioid-prescribing-united-states-before-after-centers-disease-control-prevention">declined somewhat in recent years</a>, but a recent Mayo Clinic study found that opioid use over the past decade has <a href="https://www.bmj.com/content/362/bmj.k2833">not substantially decreased.</a>

In any case, there is widespread agreement that people in the United States still rely too much on prescription opioids — the per capita usage rates are much higher than for other countries, Humphreys noted. “We are still way out of whack on that,” he said.

Last week, Gottlieb said the agency plans to contract with the National Academies of Sciences, Engineering and Medicine to develop evidence-based guidelines for the prescribing of opioids for acute and post-surgical pain. He said that FDA analyses suggest that doctors are providing too many pills for many common pain uses. Excess pills get diverted to illicit markets or used by families or friends, he said. In other cases, the patients themselves may become addicted.

<a href="https://www.washingtonpost.com/news/to-your-health/wp/2018/02/06/fda-ramps-up-warnings-about-kratom-calling-unregulated-herb-an-opioid/?utm_term=.772d59db3fca">FDA ramps up warnings about kratom, calling unregulated herb an 'opioid'</a>

<a href="https://www.washingtonpost.com/national/health-science/a-quarter-of-adults-with-sprained-ankles-were-prescribed-opioids-in-the-er/2018/07/27/112cf916-9119-11e8-8322-b5482bf5e0f5_story.html?utm_term=.0dc59d3a6dd6">A quarter of adults with sprained ankles were prescribed opioids in the ER, study shows</a>

<a href="https://www.washingtonpost.com/national/health-science/justice-dept-to-target-opioid-manufacturers-distributors-in-new-push-to-curb-deadly-epidemic/2018/02/27/817089fa-1bd4-11e8-9de1-147dd2df3829_story.html?utm_term=.228e949413d9">Justice Dept. to target opioid manufacturers, distributors in new push to curb deadly epidemic</a>

Part of Wall Street Journal team that won the 1997 Pulitzer Prize for national reporting on AIDS 

Syracuse University, BS in journalism

Laurie McGinley covers health and medicine for The Washington Post. She focuses on the Food and Drug Administration as well as cancer research and treatment. She was previously The Post's health, science and environment editor. 

Laurie McGinley

The Washington Post

Health Care

Medical Mysteries

Science

Well+Being

Health

prism://prism.query/site,/health&limit=20

The Washington Post health section provides coverage and analysis of health, healthcare, nutrition and fitness news.